Monday, 18 May 2026
  
Login

Australia's most trusted
source of pharma news

Monday, 18 May 2026
News

Novartis notches a 'first-and-only'

Posted 18 May 2026 AM

The TGA has approved Novartis’ Rhapsido, marking the first and only BTK inhibitor to be cleared for chronic spontaneous urticaria (CSU) along with the first copycat of Seqirus’ lucrative opioid Palexia SR.

Rhapsido, which contains the active ingredient remibrutinib, is indicated for the treatment of CSU, also known as hives that have no known cause, in adult patients who remain symptomatic despite H1 antihistamine treatment.

To see the whole article, please login

Popular

Ozempic blamed in bizarre stabbing
Heartfelt goodbye from Aussie MD
What cardiologists think of Reps
Industry real estate hub unveiled
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2026 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home